Cover Image

Next-generation multitarget stool DNA vs fecal immunochemical test in colorectal cancer screening

Fecal immunochemical tests (FITs) are the most widely used noninvasive colorectal cancer (CRC) screening tests. In 2014, a US/Canadian screening study reported higher sensitivity of a multitarget stool DNA test (MSDT), which combined fecal hemoglobin measurement with molecular DNA markers, compared...

Full description

Saved in:
Bibliographic Details
Main Authors: Seum, Teresa (Author) , Niedermaier, Tobias (Author) , Heisser, Thomas (Author) , Hoffmeister, Michael (Author) , Brenner, Hermann (Author)
Format: Article (Journal) Editorial
Language:English
Published: January 2025
In: JAMA internal medicine
Year: 2025, Volume: 185, Issue: 1, Pages: 110-112
ISSN:2168-6114
DOI:10.1001/jamainternmed.2024.6149
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jamainternmed.2024.6149
Get full text
Author Notes:Teresa Seum, MSc, Tobias Niedermaier, PhD, Thomas Heisser, PhD, Michael Hoffmeister, PhD, Hermann Brenner, MD, MPH
Description
Summary:Fecal immunochemical tests (FITs) are the most widely used noninvasive colorectal cancer (CRC) screening tests. In 2014, a US/Canadian screening study reported higher sensitivity of a multitarget stool DNA test (MSDT), which combined fecal hemoglobin measurement with molecular DNA markers, compared with a commercial FIT. However, this increase in sensitivity was accompanied by a substantial loss of specificity. Despite 20-fold higher per-sample costs, use of MSDT-based screening strongly increased in the US in recent years. Recently, Imperiale et al evaluated diagnostic performance of a next-generation MSDT (NG-MSDT) in another screening colonoscopy cohort (BLUE-C study). Sensitivity was higher than that of a commercial FIT, although again specificity was lower. It was previously shown that lowering the positivity threshold of a commercial quantitative FIT could enhance diagnostic performance to be comparable to a multitarget stool ribonucleic acid (RNA) test, prompting an evaluation of whether the same approach could yield similar outcomes with the NG-MSDT.
Item Description:Online veröffentlicht: November 18, 2024
Gesehen am 27.06.2025
Physical Description:Online Resource
ISSN:2168-6114
DOI:10.1001/jamainternmed.2024.6149

Similar Items